title: [Analysis of Clinical Feature and Curative Efficacy of 30 Patients with T Cell Lymphoblastic Lymphoma].
abstract: OBJECTIVE
  To analyze clinical feature and curative efficacy of patients with T cell lymphoblastic lymphoma(T-LBL).
  
  
  METHODS
  The clinical data including clinical features, laboratorial results, survival and prognostic factors from 30 patients with T-LBL were retrospectively analyzed.
  
  
  RESULTS
  Median age of 30 cases was 24.5 years, 25 (83.3%) patients were at high-intermediate and high risk by IPI, extranodal disease was present in 73.3% of the patients, 17(56.7%) patients had bone marrow involvement and 19(63.3%) had mediastinal masses. The overall response rate(ORR) for the whole group was 80.0%, the complete response rate was 36.7%, the 3-5-year overall survival rate was 37.1% and 26.0%, respectively. Compared with NHL-like regimens, ALL-like chemotherapy could improve the survival of patients, the 3-year overall survival rate was 59.1% vs 27.3%. For adult patients, the median overall survival time was 35 months vs 13 months in HSCT group and chemotherapy group, there was a statistically significant difference(P=0.019). ECOG score, IPI score, anemia, the level of LDH and β2-MG, therapy regimens, the short-term efficacy and the level of fibrinogen were the related factors for prognosis.
  
  
  CONCLUSIONS
  T-LBL is more common in young men, with large mediastinal mass and bone marrow involvement. ALL-like chemotherapy regimens are superior to NHL-like regimens, HSCT can improve the survival and reduce the recurrence of adult patients. Chemotherapy combined with allogeneic DC/CIK immune cell treatment can be used in relapsed patients.
authors.affiliation: Department of Hematology,Peking University Third Hospital,Beijing 100191,China.
authors.forename: Ping
authors.initials: P
authors.lastname: Yang
authors.affiliation: Department of Hematology,Peking University Third Hospital,Beijing 100191,China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Department of Hematology,Peking University Third Hospital,Beijing 100191,China.
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Jing
authors.affiliation: Department of Hematology,Peking University Third Hospital,Beijing 100191,China.
authors.forename: Kai
authors.initials: K
authors.lastname: Hu
authors.affiliation: Department of Hematology,Peking University Third Hospital,Beijing 100191,China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wan
authors.affiliation: Department of Hematology,Peking University Third Hospital,Beijing 100191,China.
authors.forename: Ji-Jun
authors.initials: JJ
authors.lastname: Wang
authors.affiliation: Department of Hematology,Peking University Third Hospital,Beijing 100191,China. E-mail:xiaoyank@yahoo.com.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Ke
mesh_terms: D006801:Humans; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult